GI Dynamic CEO Schorer optimistic on Endobarrier ’ s future, despite hurdles

GI Dynamics (ASX:GID) CEO Scott Schorer has had an uphill battle over the past year. His company has faced regulatory and compliance issues, negative shareholder sentiment and a number of other concerns. But Schorer and his team are committed to righting the ship and saving a product they see as having no equal in the current marketplace – even if that turnaround requires difficult decisions be made. “The main guiding light at GI Dynamics is that the EndoBarrier is a phenomenal product,” Schorer told MassDevice.com in an interview. “We are firmly committed to making sure that this technology survives for the patients and the shareholders. It’s worth saving.” The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract to treat Type II diabetes and obesity. Schorer, who is slated to speak at the upcoming DeviceTalks conference in October, said that he and the people at GI Dynamics see a huge potential in the EndoBarrier for treating individuals with Type II diabetes that other devices and treatments don’t currently provide. “There’s a dire need to address Type II diabetes, because it’s not being addressed. The treatment is not being addressed. The disease state progression is not being attenuated by drugs or gastric bypass. Neither are sufficient, so there needs to be something, and as far as we know, this is the only thing on the horizon that attack...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Diabetes Weight loss GI Dynamics Source Type: news